胃肠道动力障碍使贝赫特综合征复杂化:描述了一种新认可的临床表型
Desmond P Kidd1, Helen Kibrom2, Elizabeth Ssendi3
1The National Behçet's Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK. desmond.kidd@nhs.net.
Clinical and experimental rheumatology
|October 30, 2023
概括
胃肠不运动,一种影响肠道运动的疾病,在贝赫塞综合征 (BS) 中新发现. 阿菲雷西斯疗法在治疗肠道症状和BS的全身特征方面表现有前途.
科学领域:
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 胃肠道不运动与各种自身免疫和自身炎症性疾病有关.
- 这种情况以前没有在 Behçet 综合征 (BS) 中描述过.
研究的目的:
- 为了调查在贝赫特综合征中发生的胃肠道动力障碍.
- 评估阿菲雷斯在治疗BS患者的胃肠功能障碍和全身特征方面的疗效.
主要方法:
- 研究了七名患者的队列,这些患者的症状和调查与与免疫相关的胃肠机动性障碍或肠道神经病变相匹配.
- 作为一种新的治疗方法,进行了一项对非瑞斯的试验.
主要成果:
- 该研究描述了患者队列中的临床特征和调查结果.
- 在肠道神经病变和贝希特综合征的全身特征方面,阿菲雷西斯治疗带来了积极的反应.
- 尽管患者先前接受了最大免疫抑制疗法,但仍观察到这种反应.
结论:
- 在贝希特综合征中,胃肠道不运动会发生.
- 阿菲雷西斯是一种有效的治疗方法,用于BS的胃肠道动力障碍.
- 需要进一步的研究,以阐明免疫机制,是治疗反应的基础上的治疗反应的apheresis.
相关概念视频
Gastrointestinal Motility Disorders
394
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
394
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
272
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
272
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
167
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
167
Chronic Bowel Disorders: Introduction
459
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
459
Irritable Bowel Syndrome I: Introduction
284
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
284
Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186


